In Re: Generic Pharmaceuticals Pricing Antitrust LitigationDate Filed: August 15, 2016
District Court: Eastern District of Pennsylvania – MDL No. 525; MDL No. 2724
Nature of Suit: Antitrust
Defendant Type: Pharma
Plaintiff Type: State, Private
Court Document: https://www.bloomberglaw.com/public/desktop/document/In_re_Genenric_Drug_Pricing_Antitrust_Litig_No_MDL_2724_2018_BL_1?1528398083; http://www.paed.uscourts.gov/documents2/mdl/mdl2724
Plaintiffs are attorney generals from 48 states, Puerto Rico, and the District of Columbia, as well as classes of private plaintiffs that filed an antitrust enforcement action against nearly 20 generic drug companies. The lawsuit, originally filed in August 2016 and now consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania, alleges that generic manufacturers colluded to fix the prices of more than 300 generic drugs, in violation of the Sherman Antitrust Act and state antitrust laws. Defendants are alleged to have effectuated the alleged conspiracy through direct company-to-company contacts and through joint activities undertaken through trade associations, in particular meetings of the Generic Pharmaceutical Association. The allegations stem from the same government investigation into anticompetitive conduct in the generic pharmaceuticals industry. Read more on The Source Blog.